rs757926581
Variant summary
Our verdict is Pathogenic. The variant received 15 ACMG points: 15P and 0B. PM1PM2PP2PP3_ModeratePP5_Very_Strong
The NM_000404.4(GLB1):c.1343A>T(p.Asp448Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000744 in 1,612,986 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000404.4 missense
Scores
Clinical Significance
Conservation
Publications
- GM1 gangliosidosisInheritance: AR Classification: DEFINITIVE Submitted by: Myriad Women’s Health, ClinGen
- GM1 gangliosidosis type 3Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp
- mucopolysaccharidosis type 4BInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, ClinGen, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- GM1 gangliosidosis type 1Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet
- GM1 gangliosidosis type 2Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 15 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000659 AC: 1AN: 151796Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.0000160 AC: 4AN: 249574 AF XY: 0.0000222 show subpopulations
GnomAD4 exome AF: 0.00000753 AC: 11AN: 1461066Hom.: 0 Cov.: 31 AF XY: 0.00000826 AC XY: 6AN XY: 726800 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000658 AC: 1AN: 151920Hom.: 0 Cov.: 31 AF XY: 0.0000135 AC XY: 1AN XY: 74250 show subpopulations ⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5.
ClinVar
Submissions by phenotype
Mucopolysaccharidosis, MPS-IV-B Pathogenic:1
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
GM1 gangliosidosis;C0086652:Mucopolysaccharidosis, MPS-IV-B Pathogenic:1
This sequence change replaces aspartic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 448 of the GLB1 protein (p.Asp448Val). This variant is present in population databases (rs757926581, gnomAD 0.02%). This missense change has been observed in individual(s) with GM1 gangliosidosis (PMID: 20175788, 29439846). ClinVar contains an entry for this variant (Variation ID: 344790). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt GLB1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects GLB1 function (PMID: 20175788). For these reasons, this variant has been classified as Pathogenic. -
GM1 gangliosidosis Pathogenic:1
The GLB1 c.1343A>T (p.Asp448Val) missense variant has been reported in three studies in which it was found in a total of three individuals with GM1 gangliosidosis, including one in a homozygous state and two in a compound heterozygous state (Hofer et al. 2010; Higaki et al. 2011; Lei et al. 2012). The p.Asp448Val variant was absent from 50 controls and is reported at a frequency of 0.00023 in the East Asian population of the Exome Aggregation Consortium but this is based on two alleles in a region of good sequence coverage so the variant is presumed to be rare. Functional studies demonstrated that expression of the p.Asp448Val variant in COS-1 cells resulted in no detectable beta-galactosidase activity compared to wild type GLB1 (Hofer et al. 2010). Based on the evidence, the p.Asp448Val variant is classified as likely pathogenic for GM1 gangliosidosis. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
Mucopolysaccharidosis, MPS-IV-B;C0268271:Infantile GM1 gangliosidosis;C0268272:GM1 gangliosidosis type 2;C0268273:GM1 gangliosidosis type 3 Pathogenic:1
- -
GM1 gangliosidosis type 2 Pathogenic:1
Same nucleotide change resulting in same amino acid change has been previously reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least three similarly affected unrelated individual (PMID: 20175788, 23151865, 29439846, PM3_S). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.0000160, PM2). Each parent is heterozygous for the variant (3billion dataset). Missense changes are a common disease-causing mechanism (PP2). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.832, 3Cnet: 0.972, PP3). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. -
Infantile GM1 gangliosidosis Other:1
Most common pathogenic variant in persons of Korean ancestry with late-infantile GM1 gangliosidosis; also documented in persons of Chinese and Turkish ancestry with infantile GM1 gangliosidosis -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at